New Zealand markets open in 1 hour 35 minutes
  • NZX 50

    11,847.15
    +58.12 (+0.49%)
     
  • NZD/USD

    0.6351
    -0.0016 (-0.25%)
     
  • ALL ORDS

    7,361.90
    +37.00 (+0.51%)
     
  • OIL

    86.79
    -2.62 (-2.93%)
     
  • GOLD

    1,790.80
    -7.30 (-0.41%)
     

Why Sanofi May Be a Frontrunner in Endemic COVID-19

·4-min read
Why Sanofi May Be a Frontrunner in Endemic COVID-19

Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting